Compare MUX & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MUX | AURA |
|---|---|---|
| Founded | 1979 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 733.1M | 631.6M |
| IPO Year | 1994 | 2021 |
| Metric | MUX | AURA |
|---|---|---|
| Price | $9.17 | $6.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $28.40 | $16.60 |
| AVG Volume (30 Days) | ★ 1.3M | 683.9K |
| Earning Date | 11-09-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $197,553,000.00 | N/A |
| Revenue This Year | $19.23 | N/A |
| Revenue Next Year | $34.88 | N/A |
| P/E Ratio | $96.10 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.59 | $4.73 |
| 52 Week High | $29.70 | $9.54 |
| Indicator | MUX | AURA |
|---|---|---|
| Relative Strength Index (RSI) | 22.06 | 50.15 |
| Support Level | N/A | $6.65 |
| Resistance Level | $20.62 | $7.18 |
| Average True Range (ATR) | 0.82 | 0.44 |
| MACD | -0.40 | -0.00 |
| Stochastic Oscillator | 0.34 | 40.79 |
McEwen Inc is a mining and minerals production and exploration company that focuses on precious and base minerals in Argentina, Mexico, and the United States. The company generates its revenue from gold and silver production. It owns and operates the wholly-owned El Gallo 1 mine in Mexico and holds a minority stake in the company that manages the San Jose mine in Argentina. Its Other operations include: Fox Complex, Gold Bar Complex, Project Fenix, and Los Azules. The company generates its revenue from gold and silver production. Its operating segments include Canada, United States, Mexico, MSC and McEwen Copper, of which it derives maximum revenue from USA.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.